🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Gabapentin - what is it good for (absolutely nothing?) In this paper, we explore what proportion of gabapentin use has at least some evidence of benefit for patients. #medtwitter #pain 👇1/8 pubmed.ncbi.nlm.nih.gov/37794261/

This was a fun paper looking more into relationships in medication-taking among families, with huge credit to our former Center for Healthcare Delivery Sciences fellow, Renee Barlev, for getting it started

Nice editorial in Circ: CQO written by Julie Lauffenburger and Cynthia Jackevicius about prescription drug discount programs and out-of-pocket costs in #Cardiovascular disease! ahajournals.org/doi/10.1161/CI…

Are pre-visit patient portal messages emphasizing "how" to get a COVID-19 booster more effective than "why"? See our trial results (led by Nancy Haff) from our The National Institute on Aging (NIA)-funded Roybal Center. Center for Healthcare Delivery Sciences Niteesh Choudhry ideas42 Punam Keller 🔖bit.ly/3u3rg8u JGIM Journal of General Internal Medicine

Before heading out for some Thanksgiving downtime, I am thankful to share about my promotion last week to Associate Professor - particularly the best to have happened the same day as Rishi J Desai ! Very grateful for mentors, colleagues & trainees especially Center for Healthcare Delivery Sciences

Come work with our expanding team on pragmatic trials!

Our new study, published yesterday on Nature Digital Medicine tackles medical adherence. A short thread on what we did follows: nature.com/articles/s4174… 1/n

Thrilled to see our The National Institute on Aging (NIA)-funded trial published! Our findings indicate that personalized text messaging can improve #adherence to medication and using reinforcement learning may be a strategy to implement personalization at scale Thanks to all those involved in the project!

This is a great and thoughtful paper on using CDS for hypertension! ⬇️ Well done Lipika Samal & team!

Come work with us on data analyses of pragmatic trials and other related research!

Please consider completing and/or re-tweeting! Highly important topic.

Reminder in 1 week, join us for “Advances in Cardiovascular Health Monitoring to Support Healthy Aging at Home” 🗓️June 11, 3pm EDT 🔗Register: bit.ly/3WOW5dn FEATURING! Dr. Anna Barnacka, CEO of MindMics Edward J Wang, CEO of Billion Labs | Asst Prof UCSD Engineering

New study led by @KatharinaJungo Once an older adult starts a high-risk medication, what factors make them more likely to become chronic users? Turns out it's complicated, but here we break it down by high-risk medication class 👇 #MedTwitter pubmed.ncbi.nlm.nih.gov/39215549/

The Roybal Center for Therapeutic Optimization Using Behavioral Science is thrilled to announce its annual call for pilot project proposals for our next year of funding (beginning June 1, 2025). c4hds.org/roybal-center-… Julie Lauffenburger Niteesh Choudhry The National Institute on Aging (NIA) @NIA_BSR

Quantifying Pill Disutility Associated with Starting Versus Continuing Cardioprotective Medication: A Randomized Experiment @alexchaitoff Julie Lauffenburger #AHAJournals ahajrnls.org/3ZLNHwi

New work led by Alexander Chaitoff in Annals of Int Med finding that new use of gabapentin is not associated with greater fall risk than another active comparator - excellent work, Alex! 👏